PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Adalimumab - Localised Psoriasis

PAD Profile : Adalimumab - Localised Psoriasis

Keywords :
Biologic, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Dermatology, biosimilar, high impact sites, PGA, Physicians Global Assessment
Brand Names Include :
Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 July 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree the following immunomodulators for use in localised psoriasis

  • Etanercept    
  •  Infliximab
  • Adalimumab    
  •  Ustekinumab    
  • Secukinumab
  • Ixekizumab 
  • Certolizumab   
  • Guselkumab

For use in the following body areas
•    Head and neck – includes face and scalp
•    Nails
•    Genitals
•    Hands and feet
•    Flexures

These are all RED drugs, and the Dermatology teams will complete Blueteq forms for initiation and continuation.

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More